UNSPSC 51101922: Artenimol

This classification denotes an antimalarial agent with the molecular formula C15H24O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6A9O50735X, chemically known as (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3,-j)-1,2-benzodioxepin-10-ol but generally known as artenimol, which bears US NIH Compound Identifier 179336. European Medicines Agency schedules Artenimol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30709.

UNSPSC 51101922 Artenimol is a Commodity-tier code that does not match the work actually being solicited under it in recent state and local opportunities. The code's nominal scope addresses a specific pharmaceutical ingredient, but the recent opportunities tagged to this code solicit naloxone distribution systems, direct-to-manufacturer pharmacy programs, emergency medical supplies, and generic multi-source pharmaceuticals and over-the-counter products — none of which involve artenimol as a procured item or service line. The mismoric tagging suggests either a data error in the procurement systems or a broad misapplication of the code to pharmaceutical procurement activity more generally. State and local issuing bodies procurement activity under this code shows little relevant recent activity aligned with the code's actual commodity definition.

The geographic mix of recent postings spans Florida, Texas, Minnesota, and Oregon, with issuing bodies including county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire services (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Representative opportunities include Seminole County's IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 response deadline; the City of Tampa's ITB 26P00145 for 169 line items of medical and first-aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a March 13, 2026 response deadline (sheltered for certified Small Local Business Enterprises with a 5% bid discount); the Texas Health and Human Services Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription capabilities with an April 3, 2026 response date; and Minnesota's MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities with a March 26, 2026 proposal deadline. The code's persistent misapplication to pharmaceutical procurement warrants clarification with procurement offices before investing pursuit resources.